Spero Therapeutics Inc. Stock News

Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of -11.90% and 4.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CAMBRIDGE, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commerciali

CAMBRIDGE, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializi

CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Monday, May 16, 2022, at 4:

CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Monday, May 16, 2022, at 4:30

Upgrades Craig-Hallum upgraded the previous rating for Pros Holdings Inc (NYSE:PRO) from Hold to Buy. Pros Holdings earned $0.21 in the first quarter, compared to $0.22 in the year-ago quarter. At the

Clovis (CLVS) delivered earnings and revenue surprises of -2.33% and 7.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Acadia Announces FDA AdComm For Pimavanserin In Alzheimer's-Related Psychosis The FDA's Psychopharmaco

Spero Therapeutics (SPRO) stock is taking a beating on Tuesday after the biotech company revealed a change in strategic direction. The post SPRO Stock Alert: 9 Things to Know as Spero Therapeutics Plu

Announces Immediate Cessation of Tebipenem HBr Commercialization Initiatives; Company to Shift Focus to Advancement of SPR720 and SPR206

Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced two oral presentations and four poster presentations at the 32nd European Congress of Cl

CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced two oral presentations and four poster presentations at the 32nd European Congress of Clin

CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced publication in The New England Journal of Medicine (NEJM) of the results from the Phase

Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q4 2021 Results - Earnings Call Transcript